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and healthy control subjects (n ¼ 50). We measured endothelial function (using the Endothelial Pulse Amplitude
Testing index), intima-media thickness (IMT) of the right common carotid artery (RCCA) and the left common
carotid artery (LCCA), and fasting lipid proﬁle and C-reactive protein (CRP). KD patients were classiﬁed according
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unknown etiology that occurs predominantly in infants and
young children. First described in 1967 in Japan, the disease
is now known to occur throughout the world in children of
all races and ethnicities (1). Indeed, in developed countries,
KD has now surpassed acute rheumatic fever as the leading
cause of childhood acquired heart disease and accounted for
4,000 hospitalizations in the United States in 2000 (2,3).
Treatment of KD in the acute phase is aimed at reducing
inﬂammation in the coronary artery (CA) wall and pre-
venting coronary thrombosis. CA aneurysms or ectasiaBoston Children’s Hospital, and Department of
Boston, Massachusetts; yDivision of Pediatric
, Stanford University, Stanford, California; and
sachusetts General Hospital, Harvard Medical
ported by the American Heart Association,
rd, and the Farb and McCance Family Funds.
ave no relationships relevant to the contents of
3; revised manuscript received March 31, 2013,develop in w20% to 25% of untreated children with the
disease and may lead to myocardial infarction, sudden death,
or ischemic heart disease (4). Administration of high-dose
intravenous gamma globulin within the ﬁrst 10 days of
illness lowers the risk of CA aneurysms to 5% and of giant
aneurysms to 1% (5).
See page 1122
Patients with persistent aneurysms have systemic inﬂam-
mation years after disease onset, as evidenced by C-reactive
protein (CRP) levels that are signiﬁcantly higher than those
seen in healthy children (6,7). Studies in these patients with
persistent CA lesions have demonstrated endothelial
dysfunction (8–10). In patients with persistent aneurysms,
the carotid intima-media thickness (IMT) also has been
found to be thicker than in control patients (8). Similar
ﬁndings have been observed in KD patients with regressed
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1115aneurysms (11,12). The data, however, are conﬂicting in KD
patients without a history of CA dilation (9,12,13).
To assess the determinants of vascular function, we per-
formed a single-center study in a population of North
American adolescents and young adults with a history of KD.
CA lesions and medical history were meticulously charac-
terized. We used different modalities to assess vascular
health, including endothelial function testing and carotid
ultrasound.
Methods
Subjects. We studied patients with KD followed at Boston
Children’s Hospital in whom KD onset occurred at least 12
months before the study visit and whose current age was 11
to 29 years. Control subjects of similar age and sex were
recruited through community listing. Exclusion criteria for
both KD and control subjects included a history of structural
heart disease, latex allergy, and the presence of a condition
that might affect vascular function such as rheumatological
disease, diabetes, and other chronic medical conditions.
Vascular testing was deferred for at least 4 weeks in subjects
with acute illness (i.e., febrile illness or viral syndromes).
Signed consent was obtained from a parent or guardian for
patients younger than 18 years of age or from the participant
when 18 years of age or older. Participants younger than
18 years of age gave assent. The study was approved by
the institutional review board of the Boston Children’s
Hospital.
Testing. Subjects were asked to fast overnight for 12 h
except for the consumption of water. The subject’s weight and
height were measured using a Scale-Tronix 5002 stand-on
scale (Scale-Tronix, Wheaton, Illinois) and a SECA 240
mechanical, high-precision measuring rod (Seca, Hamburg,
Germany). Blood pressure was measured on the dominant
arm in the sitting position using the oscillometric method
(Dinamap, GE,Waukesha,Wisconsin) after at least 5 min of
resting. Four blood pressure measurements were obtained,
and measurements 2 through 4 were averaged.
ENDOTHELIAL PULSE AMPLITUDE TESTING. The Endothelial
Pulse Amplitude Test (Endo-PAT) is a U.S. Food and Drug
Administration–approved device that is based on the prin-
ciple of reactive hyperemia. It has been validated in adults and
studied in several high-risk pediatric groups (14–18). A lower
Endo-PAT index indicates worse CA health. The Endo-
PAT testing protocol, as described previously (14) (Itamar
Medical Ltd, Caesarea, Israel) was performed in the morning
or early afternoon (starting time between 7:30 AM and 11:30
AM). The Endo-PAT data were analyzed with the proprietary
software package, without any input from the examiner. The
Endo-PAT index was deﬁned as the ratio of the average pulse
amplitude during the 1-min period beginning after exactly
90 s of reactive hyperemia compared with the average pulse
amplitude during the 210-s pre-occlusion baseline period.
We have shown excellent feasibility and reproducibility
of this modality in healthy adolescents previously (14).Participants were asked to grade
discomfort/pain immediately af-
ter the test was completed.
CAROTID ULTRASOUND. We per-
formed carotid ultrasound exam-
inations to detect structural and
functional arterial abnormalities
in the carotid arteries. Increased
thickness of the intimal-medial
portion of the carotid artery is
a marker of the presence of
atherosclerosis (19). In addition,
carotid arterial stiffness demon-
strated by ultrasonography has
been reported to be associated
with cardiovascular events (20).
Recently, Doppler ultrasound has been used as a method to
evaluate not only signiﬁcant stenosis or plaque formation but
also hemodynamic alterations in the common carotid artery
(CCA) in hypertensive patients (21). The right CCA
(RCCA) and left CCA (LCCA) were examined in longitu-
dinal and transverse planes using high-resolution B-mode
gray-scale and color duplex ultrasonography (22). The carotid
IMT of the far wall of the artery was measured in anterior,
posterior, and lateral angulations in a zoomed mode across
a 1-cm segment at the distal end of the CCA, proximal to the
carotid bulb. Edge detection software was used (iE33 system,
Q lab, Philips, Andover, Massachusetts). A pulsed-wave
Doppler sample was placed in the CCA and internal
carotid artery for systolic and diastolic velocity acquisition and
to measure the pulsatility index ([peak systolic velocity 
minimum diastolic velocity]/mean velocity) (23). Cross-
sectional dimensions of the CCA in systole and diastole
were measured in triplicate and averaged to calculate the
arterial pressure–strain elastic modulus (24). The ultrasound
probes were calibrated for axial and lateral resolution using an
ultrasound phantom to ensure accuracy and consistency of
measurements. The inter- and intraobserver percentages of
error for carotid IMT measurement were <2%. The inter-
observer intraclass correlation coefﬁcients for pressure–strain
elastic modulus were 0.828 (95% conﬁdence interval: 0.566 to
0.932) and 0.778 (95% conﬁdence interval: 0.439 to 0.912)
for the RCCA and LCCA, respectively.
LABORATORY ANALYSIS. Fasting lipid proﬁle (total choles-
terol, high-density lipoprotein cholesterol, and triglyceride
levels), and CRP level were collected on the day of the visit
after the vascular tests were completed.
LIFESTYLE AND DIET. A set of questionnaires about each
patient’s lifestyle and clinical and family history was
completed on the day of the visit. A dietary recall of all food,
beverages, vitamins, and supplements consumed by the
subjects in the 24 h preceding testing was obtained. Subjects
were also asked to report any exercise or physical activity
performed in the 24 h preceding testing. These data were
Table 1 Demographics
KD Group
(n ¼ 203)
Control Group
(n ¼ 50) p Value
Age at testing, yrs 16.73  4.21 17.57  4.33 0.22
Male 122 (60%) 29 (58%) 0.87
Height, cm 166 (136–195) 165 (148–188) 0.55
Weight, kg 61 (29–123) 60 (39–109) 0.70
Body mass index, kg/m2 22.74  4.81 21.94  3.81 0.21
Body surface area, m2 1.70  0.29 1.69  0.22 0.72
Blood pressure, mm Hg
Systolic 118  12.53 117  13.15 0.56
Diastolic 72  9.05 70  9 0.12
Mean 84  9 80  10 0.02
Sex by age group 0.91
11 to 19 yrs 161 (102 male, 50%) 38 (23 male, 46%)
20 to 29 yrs 42 (20 male, 10%) 12 (6 male, 12%)
Days from last menstrual cycle to testing (n ¼ 64, n ¼ 19) 19 (0–375) 14 (2–35) 0.43
Race 0.39
White 162 (80%) 38 (76%)
Black/African American 11 (5%) 5 (10%)
Asian 18 (9) 4 (8%)
Multiple races 5 (2%) 2 (4%)
Other 1 (<1%) 1 (2%)
Unknown 6 (3%) 0 (0%)
Ethnicity 0.68
Hispanic 12 (6%) 2 (4%)
Non-Hispanic 187 (92%) 48 (96%)
Smoker 6 (3%) 3 (6%) 0.39
Values are mean  SD, n (%), or median (range).
BMI ¼ body mass index; BSA ¼ body surface area; KD ¼ Kawasaki disease.
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ware, version 10.1 (Salem, Oregon) to assess for average daily
intake of saturated and unsaturated fats and select vitamins, as
these factors are known to affect endothelial function.
Subjects reported a detailed clinical medical history including
current medications, vitamins, and supplements. Subjects
were asked to report all regular physical activity performed
during the year before testing. We categorized activity as
vigorous or moderate using the reference list of metabolic
equivalents by Ainsworth et al. (25). Activities with metabolic
equivalent values of 6 were classiﬁed as vigorous. Subjects
were also asked to give a detailed summary of the number of
hours they spent doing sedentary activities such as quiet play,
computer time, television time, and reading/homework in the
week before testing as well as the average number of hours
spent sleeping each night in the past year.
CLINICAL AND FAMILY HISTORY. Additional clinical medical
data were gathered from subjects’ medical records including
details about the acute phase of the disease, such as the date
of fever onset, KD symptoms, treatment, and CA status. In
addition, participants reported family history for ﬁrst- and
second-degree relatives.
Statistical analysis. Patient characteristics including demo-
graphic information, lipid proﬁle, nutrition information,
exercise variables, and vascular testing results were compared
for the KD and control groups using the Fisher exact test forcategorical variables and either the Wilcoxon rank sum test or
unpaired t test for continuous variables. Continuous variables
are presented as mean  SD if the values were normally
distributed and median (range) if not normally distributed,
unless otherwise noted. The primary outcome variable was the
Endo-PAT index. Analyses of all other vascular testing vari-
ables are considered exploratory; the p values presented have
not been adjusted for multiple comparisons. Additional anal-
yses were performed categorizing KDpatients into 4 subgroups
by their worst-ever CA status; comparisons of continuous
variables were made using either the Kruskal-Wallis test or 1-
way analysis of variance. Patients were classiﬁed according to
their worst-ever CA status: group I, always normal CAs; group
II, CA z-scores2 but<3; group III, CA z-scores3 but<8
mm; and group IV, giant CA aneurysm (8 mm) (26). The z-
scores were based on the dimensions of the proximal left
anterior descending or proximal right CA (26). In a secondary
analysis in whichCAdimensions were classiﬁed only according
to the z-score, group III included patients with CA z-
scores 3 but <10, and group IV (giant aneurysms) included
patients withCA z-scores of10 (27). In additionwe analyzed
the data omitting any patient who admitted to smoking.
Results
Demographics. KD patients did not differ signiﬁcantly
from the control group in age, body size, systolic and
Table 3 Coronary Artery Status (n ¼ 203)*
Worst ever
No coronary artery enlargement (group I) 136 (67%)
Ectasia (z-score [>¼ sign] 2, but <3) (group II) 20 (10%)
Ectasia (z-score 3), aneurysm (<8 mm) (group III) 40 (20%)
Giant aneurysms (8 mm) (group IV) 7 (3%)
Current
No coronary artery enlargement 156 (77%)
Ectasia (z-score [>¼ sign] 2, but <3) 2 (1%)
Ectasia (z-score 3), aneurysm (<8 mm) 4 (2%)
Giant aneurysms, 8 mm 6 (3%)
Regressed ectasia, aneurysms 35 (17%)
Values are n (%). *z-Scores are based on measurements of the proximal left anterior descending or
proximal coronary arteries.
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1117diastolic blood pressure, sex, race, or ethnicity (Table 1). The
mean blood pressure in the KD group was higher than that
in the control group (84  9 mm Hg vs. 80  10 mm Hg,
p ¼ 0.02). The groups also had similar lipid proﬁles, CRP
levels, and other medical history data, including variables
related to smoking, 24-h nutrition, and exercise (Table 2).
There was a trend toward increased CRP levels in the KD
group (0.1 mg/dl [range, 0.1 to 3.1 mg/dl] vs. 0.1 mg/dl
[range, 0.1 to 0.4 mg/dl], p ¼ 0.06). The control group,
compared with the KD group, included a greater percentage
who had smoked within 24 h before testing (10% vs. 1%,
p ¼ 0.001, 2 of these control subjects do not consider
themselves smokers) and a lower percentage with a family
history of hypertension (58% vs. 78%, p ¼ 0.001).
KD history. The majority of the patients had typical KD
(n ¼ 187, 92%). Eight KD patients had atypical KD. In 8
patients who received their initial treatment at an outside
hospital, the original clinical observations were unavailable.
Intravenous gamma globulin was administered to 188 patients
(93%) at a median of 6 days (range, 0 to 23 days) from fever
onset. Table 3 classiﬁes the patients by their worst-ever and
current CA status. When classiﬁed by their worst-ever status,
KD patients included 136 (67%) in group I, 20 (10%) in
group II, 40 (20%) in group III, and 7 (3%) in group IV. AtTable 2 Blood Work, Nutrition, and Exercise
KD (n ¼ 203) Control (n ¼ 50) p Value
Lipid proﬁle and CRP
TC, mg/dl 153 (91–279) 151 (86–229) 0.34
HDL, mg/dl 53.7 (26.6–108.6) 53.6 (28.5–90.7) 0.63
TC/HDL 2.78 (1.36–5.36) 2.86 (2–4.82) 0.61
Triglycerides, mg/dl 67 (21–248) 65 (34–186) 0.99
LDL, mg/dl 85 (20–162) 87 (33–145) 0.59
CRP, mg/dl 0.1 (0.1–3.1) 0.1 (0.1–0.4) 0.06
Nutrition intake in the
24 h before testing
Monosaturated fat, g 12 (0–184) 10 (0–73) 0.25
Polysaturated fat, g 5 (0–332) 4 (0–46) 0.24
Saturated fat, g 27 (1–184) 23 (1–101) 0.18
Omega 3, g 0.3 (0–37) 0.3 (0–6.1) 0.53
Omega 6, g 3 (0–295) 3 (0–45) 0.25
Vitamin A
carotenoid (RE)
31 (0–6,737) 40 (0–3.596) 0.52
Vitamin E, mg 3 (0–80) 3 (0–60) 0.55
Beta-carotene, mg 117 (0–13,016) 109 (0–16,959) 0.82
Exercise activity in the
year before testing
Vigorous activity,
h/week
6 (0–115) 4 (0–40) 0.57
Moderate activity,
h/week
3 (0–42) 3 (0–15) 0.29
Sedentary activity
(h/previous week)
30 (0–113) 33 (2–94) 0.37
Sleep, h/night 8 (0–12) 8 (4–13) 0.66
Values are median (range).
CRP ¼ C-reactive protein; HDL ¼ high-density lipoprotein cholesterol; KD ¼ Kawasaki disease;
LDL ¼ low-density lipoprotein cholesterol; Omega 3 ¼ omega 3 fatty acids; Omega 6 ¼ omega 6
fatty acids; RE ¼ retinol equivalent; TC ¼ total cholesterol.a median of 11.6 years (range, 1.2 to 26 years) after KD onset,
10 of 203 patients (5%) had persistent CA aneurysms.
Vascular health testing. Table 4 summarizes the results of
the vascular testing in the overall KD group and control
group. No statistically signiﬁcant difference was found for
the primary outcome of Endo-PAT index. Compared with
control subjects, KD patients tended to have higher peak
velocity in the LCCA (127  23 cm/s vs. 120  20 cm/s,
p ¼ 0.04) and a higher pulsatility index of both the RCCA
and LCCA (1.26  0.36 vs. 1.13  0.28, p ¼ 0.006 and
1.23  0.33 vs. 1.14  0.27, p ¼ 0.05, respectively). The
groups did not differ signiﬁcantly in the measures of
endothelial function, in IMT of RCCA and LCCA, or in
stiffness of the RCCA and LCCA. No plaques were iden-
tiﬁed in the patient or control group by carotid ultrasound.
KD patients and controls reported a similar degree of
discomfort after administration of Endo-PAT testing.
We also compared mean values on Endo-PAT testing
and carotid ultrasound among the four KD subgroups and
the control group (Table 5, Figs. 1 and 2). KD subgroups
and control group had similar vascular health indices and
CRP levels. Risk factors for atherosclerotic CA disease,
including lipid proﬁle, blood pressure and history of
smoking, were equivalent within KD subgroups classiﬁed
according to worst-ever CA status.
In further subgroup analyses, there were no signiﬁcant
differences in Endo-PAT and carotid ultrasound variables
between the control group and either those with persistent
aneurysms (combined groups III and IV) or those with giant
aneurysms (group IV).When comparing patients with current
CA aneurysms after KD (n ¼ 10), no current CA aneurysms
after KD (n ¼ 191), and the control group (n ¼ 50), KD
patients without current CA aneurysms and KDpatients with
current CA aneurysms showed a trend toward increased
LCCA IMT (0.459  0.046 mm vs. 0.436  0.033 mm vs.
0.434 0.028mm, p¼ 0.06, 1-way analysis of variance). This
observationwas similar inCRP levels (0.1mg/dl [range, 0.1 to
3.1 mg/dl] vs. 0.1 mg/dl [range, 0.1 to 1.7 mg/dl] vs. 0.1 mg/l
[range, 0.1 to 0.4 mg/dl], p ¼ 0.06, Kruskal-Wallis test).
In a secondary analysis, we deﬁned giant aneurysms as those
with a z-score 10, in contrast to the traditional deﬁnition
Table 4 Vascular Testing in KD and Control Populations
KD (n ¼ 203) Control (n ¼ 50) p Value
Endo-PAT
Endo-PAT index n ¼ 201 n ¼ 50
Mean  SD 1.78  0.46 1.70  0.53 0.35
Median, range 1.74 (1.0–3.07) 1.55 (1.0–3.51) 0.13
Log Endo-PAT index 0.54  0.26 0.49  0.29 0.23
Reported pain level* 0.82
0 48 (24%) 12 (24%)
1 71 (35%) 17 (34%)
2 60 (30%) 16 (32%)
3 21 (10%) 4 (8%)
4 1 (<1%) 1 (2%)
5 1 (<1%) 0 (0)
Carotid artery ultrasound 203 (100%) 50 (100%) d
Right carotid artery
CCA IMT, mmy 0.428  0.024 0.432  0.029 0.35
CCA peak velocity, cm/s (n ¼ 201, n ¼ 48) 124  24 118  20 0.07
CCA elastic modulus, mm Hg (n ¼ 201, n ¼ 50) 277  93 303  98 0.09
ICA peak velocity, cm/s (n ¼ 202, n ¼ 49) 94  21 90  28 0.45
ICA end-diastolic velocity, cm/s (n ¼ 202, n ¼ 50) 33  7 34  9 0.39
ICA pulsatility index (n ¼ 200, n ¼ 49) 1.26  0.36 1.13  0.28 0.006
Left carotid artery
CCA IMT, mm 0.438  0.034 0.434  0.028 0.42
CCA peak velocity, cm/s (n ¼ 200, n ¼ 48) 127  23 120  20 0.04
CCA elastic modulus, mm Hg (n ¼ 201, n ¼ 50) 282  100 295  89 0.34
ICA peak velocity, cm/s (n ¼ 201, n ¼ 50) 97  23 91  22 0.11
ICA end-diastolic velocity, cm/s (n ¼ 201, n ¼ 50) 35  9 35  9 0.93
ICA pulsatility index (n ¼ 201, n ¼ 50) 1.23  0.33 1.14  0.27 0.05
Values are mean  SD, median (range), or n (%). *Wong-Baker Faces Pain Scale, ranging 0 to 5. yAverage value of the IMT measurements in the
anterior, posterior and lateral planes.
CCA ¼ common carotid artery; Endo-PAT ¼ endothelial pulse amplitude testing; ICA ¼ internal carotid artery; IMT ¼ intima-media thickness; KD ¼
Kawasaki disease.
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1118of8 mm in maximum diameter used in the primary analysis.
This lower threshold for the deﬁnition of giant aneurysms
resulted in reclassiﬁcation of 8 patients from group III to group
IV. There were no longer any signiﬁcant differences among the
subgroups in measures of vascular health.
Our study entry criteria did not exclude smokers. Six of
the 203 KD patients were smokers or admitted to smoking,
whereas 3 of 50 control subjects reported to be smokers (3%
vs. 6% respectively, p ¼ 0.39). In a secondary analysis that
excluded smokers, study inferences were unchanged.
Discussion
American Heart Association guidelines suggest that the long-
term management of patients with KD be tailored to the
degree of CA involvement (5). These recommendations, in
contrast to Japanese guidelines (28), include lifetime follow-up
for cardiovascular risk assessment and counseling every 3 to
5 years for KDpatients who never hadCA enlargement or had
only transient CA ectasia. However, the risk of long-term
adverse effects of KD on the coronary and peripheral vascu-
lature among those who never had CA abnormalities is
controversial. Some studies in this subgroup have shown
preclinical abnormalities in endothelial function, IMT, arterial
stiffness, and myocardial reserve (10,12,13,29–32), whereasothers have not (33,34). Delineation of vascular sequelae is
important because clinical or subclinical inﬂammation of the
coronary and systemic arteries may form the substrate for
longer term functional and structural abnormalities and
increase the risk of premature atherosclerosis (7,35,36). In
adults, peripheral vascular abnormalities are associated with
CA health, but uncertainty about peripheral vascular abnor-
malities amongKD patients with always normal CAs fuels the
ongoing debate about their need for serial long-term cardiac
follow-up (37,38).
In the current study, comprising the largest North Amer-
ican series of KD patients with vascular function testing to
date, peripheral vascular health was evaluated at a mean of
>11 years after illness onset. We found that the pulsatility
index, which has been shown to be independently associated
with high-sensitivity CRP levels in patients with essential
hypertension (39), was higher in our KD population than in
the control group. Similarly, a recent paper by Maurice and
Dahdah (40) reported abnormal ascending aortic mechanical
properties in KD patients compared with controls when
measured by wall strain. However, in our study, KD patients
with a history of normal CAs by 6 to 8 weeks after disease
onset did not differ from healthy control subjects with respect
to endothelial function, carotid IMT, and carotid stiffness.
Table 5 Control Group and KD Patients by Worst Ever Coronary Artery Status
Control Group
(n ¼ 50)
No CA Enlargement
(Group I)
(n ¼ 136)
Ectasia
(z 2, <3)
(Group II)
(n ¼ 20)
Ectasia (z 3,
Aneurysm <8 mm)
(Group II)
(n ¼ 40)
Giant Aneurysm
(8 mm)
(Group IV)
(n ¼ 7) p Value
Endo-PAT
Endo-PAT index 1.70  0.53 1.79  0.44 1.85  0.46 1.72  0.53 1.62  0.35 0.55
Logarithm of Endo-PAT index 0.49  0.29 0.56  0.24 0.59  0.24 0.49  0.30 0.46  0.20 0.35
Pain scale 1 (1, 2) 1 (1, 2) 1 (0, 2) 1 (0, 2) 1 (1, 2) 0.08
Carotid ultrasound
Right CCA IMT,* mm 0.432  0.03 0.429  0.02 0.428  0.03 0.424  0.02 0.440  0.04 0.41
Left CCA IMT,* mm 0.434  0.03 0.439  0.04 0.425  0.02 0.434  0.03 0.467  0.05 0.05
Right CCA elastic modulus, mm Hg 303  98 277  97 294  71 274  95 242  42 0.31
Left CCA elastic modulus, mm Hg 295  89 280  100 288  86 283  116 289  73 0.92
Right CCA peak velocity, cm/s 118  20 125  23 129  30 121  23 116  18 0.23
Left CCA peak velocity, cm/s 120  20 127  21 128  21 127  28 127  25 0.42
Right ICA peak velocity, cm/s 90  28 94  20 91  20 93  24 89  25 0.84
Left ICA peak velocity, cm/s 91  22 97  22 90  22 101  27 104  16 0.20
Right ICA end-diastolic velocity, cm/s 34  9 33  7 34  8 33  9 30  7 0.67
Left ICA end-diastolic velocity, cm/s 35  9 35  9 32  9 35  10 38  6 0.53
Right ICA pulsatility index 1.13  0.28 1.25  0.35 1.23  0.37 1.31  0.42 1.26  0.21 0.15
Left ICA pulsatility index 1.14  0.27 1.21  0.33 1.27  0.29 1.26  0.33 1.21  0.41 0.38
Blood work
CRP, mg/dl 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.3) 0.37
Values are mean  SD or median (25th, 75th percentiles). *Average value of the IMT measurements in the anterior, posterior and lateral planes.
CA = coronary artery; CCA = common carotid artery; ICA = internal carotid artery.
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1119Our ﬁnding of normal peripheral vascular health among
KD patients without CA abnormalities differs from ﬁndings
of some other authors (13,29,32), but is consistent with
those of other smaller studies in North America (12,33).
Potential reasons for the differences in study results in this
subgroup of KD patients include potential publication bias
in the earlier reports (i.e., positive results are more likely
to be published), differences in peripheral vascular healthFigure 1
Boxplots of the Endothelial Pulse Amplitude Testing
Index in the Kawasaki Disease Patient Groups and
the Control Group
The x indicates the subgroup mean. The comparisons were made by 1-way
analysis of variance. EndoPAT ¼ Endothelial Pulse Amplitude Testing.related to race and ethnicity, and differences in the modal-
ities used to assess vascular health.
Our study had limited power to compare vascular health
between control subjects and those with either regressed CA
aneurysms or with concurrent CA aneurysms at the time of
vascular testing. Nonetheless, patients with a history of giant
aneurysms had thicker LCCA IMT and a trend toward
lower reactive hyperemia (Endo-PAT) index, reﬂecting
worse endothelial health. Similarly, the 10 KD patients with
CA abnormalities at the time of vascular testing had a trend
toward higher LCCA IMT and increased serum CRP. The
carotid arterial wall of patients with persistent CA aneu-
rysms (8,13) has been reported to have a higher IMT and
increased stiffness, although these ﬁndings have not been
conﬁrmed by others (10).
Endothelial dysfunction has also been reported in KD
patients. Ikemoto et al. (10) demonstrated decreased brachial
artery ﬂow–mediated dilation in patients with persistent CA
aneurysms. Two other studies on endothelial function in
patients with KD reported similar results (12,29). CRP levels
have been reported to be signiﬁcantly higher in patients with
persistent CA aneurysms than those seen in normal age-
matched children or among patients with KD without
aneurysms or with regressed aneurysms, suggesting that the
presence of aneurysms is associated with persistent systemic
inﬂammation years after disease onset (41).
In patients with CA aneurysms that have regressed to
normal internal lumen diameter, histopathology shows
ﬁbrous intimal thickening (42,43). In this group, intravascular
ultrasound studies have reportedmyointimal thickening in the
Figure 2
Boxplots of the Intima-Media Thickness in Kawasaki
Disease Patient Groups and the Control Group
The x indicates the subgroup mean. The comparisons were made by 1-way anal-
ysis of variance. IMT ¼ intima-media thickness; LCCA ¼ left common carotid
artery; RCCA ¼ right common carotid artery.
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1120CAs (44,45). These arteries demonstrate abnormal endo-
thelial function with reduced vascular reactivity (11,46).
In KD patients with persistent or regressed CA aneurysms,
the proximal and peripheral arterial beds have also been re-
ported to be stiffer compared with those in control subjects
(13,47,48).
Study limitations. The strengths of the current study
included its prospectively characterized KD population, use
of CA z-scores, a large sample size for a rare disease, and the
use of reliable modalities to assess vascular health. Our study
should, however, be viewed in light of its limitations. We
had a very small group of patients with giant aneurysms. Our
population was drawn from a single site, and the predomi-
nantly non-Hispanic white study population precludes
generalization of our ﬁndings to individuals of other races or
ethnicities. Our control group consisted of North American
youth, who may have had higher prevalence of cardiovascular
risk factors than Asian control populations. A higher
percentage of control subjects admitted to smoking in the
24 h before vascular testing. We did not check serumcotinine levels for objective ascertainment of the occurrence
of smoking. However, analysis of the data omitting any
patient who admitted to smoking did not change the study
inferences. Finally, Orenstein et al. (49) recently published
a post-mortem series of KD patients, demonstrating that the
vasculopathic processes that characterize KD, including
progression to luminal myoﬁbroblastic proliferation, are
distinct from those of atherosclerosis. Thus, it is possible
that peripheral vascular health in KD patients might not
reﬂect the health of the coronary arterial bed to the same
extent as it does among individuals with atherosclerosis.
Conclusions
In summary, in contrast to some previous reports, this single-
center study of late peripheral vascular function in a large
population of North American adolescents with a history of
KD demonstrated that patients whose maximum CA
dimensions were either always normal or only mildly ectatic
(z-score <3) had vascular health indexes that were similar to
those of a healthy control group. Our study thus provides
reassurance regarding peripheral vascular health in this pop-
ulation, supporting the contention of some investigators that
these KD patients might not need lifetime specialized
surveillance (37,50). The extent to which peripheral vascular
function mirrors abnormalities in the CAs in patients with
KD who never had aneurysms will become clearer as the
earliest cohort of patients with KD enters middle age.Reprint requests and correspondence: Dr. Elif Seda Selamet
Tierney, Pediatric Heart Center, Stanford University, 750 Welch
Road, Suite 350, Mail Code: 5731, Palo Alto, California 94304.
E-mail: tierneys@stanford.edu.REFERENCES
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